Ownership and insider activity for Vertex Pharmaceuticals Incorporated (VRTX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene.
Price
| Price | $503.50 |
| Market Cap | $127.8B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-08 | van Grunsven Jasper | A-Award | 8,682 | |
| 2026-09-08 | van Grunsven Jasper | |||
| 2026-08-28 | Ambrose Kristen | A-Award | 5,000 | |
| 2026-08-27 | SACHS BRUCE I | G-Gift | 6,000 | |
| 2026-07-21 | Tatsis Ourania | A-Award | 8,251 | |
| 2026-07-21 | Sachdev Amit | A-Award | 8,251 | |
| 2026-07-15 | SACHS BRUCE I | A-Award | 99 | |
| 2026-07-15 | Garber Alan M | A-Award | 31 | |
| 2026-07-02 | Tatsis Ourania | S-Sale | 1,500 | $787K |
| 2026-07-02 | McKechnie Duncan | S-Sale | 1,541 | $800K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.18B | $1.67B | $2.65B | $3.11B | $5.99B | $6.79B | $10.50B | $10.37B | $4.57B | $5.09B |
| Short-term Investments | $250.6M | $423.3M | $518.1M | $699.0M | $670.7M | $729.9M | $274.5M | $849.2M | $1.55B | $1.52B |
| Receivables | $235.5M | $386.0M | $409.7M | $633.5M | $885.4M | $1.14B | $1.44B | $1.56B | $1.61B | $2.05B |
| Inventory | $77.6M | $111.8M | $124.4M | $167.5M | $280.8M | $353.1M | $460.6M | $738.8M | $1.21B | $1.69B |
| Total Current Assets | $1.83B | $2.65B | $3.84B | $4.82B | $8.13B | $9.56B | $13.23B | $14.14B | $9.60B | $11.20B |
| Property, Plant & Equipment | $698.4M | $789.4M | $812.0M | $833.3M | $1.28B | $1.42B | $1.46B | $1.45B | $2.58B | $3.08B |
| Goodwill | $50.4M | $50.4M | $50.4M | $1.00B | $1.00B | $1.00B | $1.09B | $1.09B | $1.09B | $1.09B |
| Intangible Assets | $284.3M | $29.0M | 0 | $400.0M | $400.0M | $400.0M | $603.6M | $839.9M | $825.9M | $424.2M |
| Total Assets | $2.89B | $3.55B | $6.25B | $8.32B | $11.75B | $13.43B | $18.15B | $22.73B | $22.53B | $26.14B |
| Accounts Payable | $61.5M | $74.0M | $111.0M | $87.6M | $155.1M | $195.0M | $303.9M | $364.9M | $413.0M | $461.7M |
| Short-term Debt | $300.0M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $92.3M | $82.8M |
| Total Current Liabilities | $792.5M | $807.3M | $1.12B | $1.33B | $1.88B | $2.14B | $2.74B | $3.55B | $3.56B | $3.86B |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $1.85B |
| Total Liabilities | $1.56B | $1.50B | $1.81B | $2.23B | $3.06B | $3.33B | $4.24B | $5.15B | $6.12B | $7.48B |
| Retained Earnings | -$5.37B | -$5.12B | -$2.99B | -$1.85B | $858.7M | $3.20B | $6.52B | $10.14B | $9.61B | $13.56B |
| Total Equity | $1.16B | $2.03B | $4.44B | $6.09B | $8.69B | $10.10B | $13.91B | $17.58B | $16.41B | $18.67B |
| Total Debt | $840.8M | $606.4M | $586.8M | $661.7M | $931.9M | $967.4M | $899.7M | $808.4M | $1.75B | $3.88B |
| Net Debt | -$593.8M | -$1.48B | -$2.58B | -$3.15B | -$5.73B | -$6.56B | -$9.88B | -$10.41B | -$4.37B | -$2.73B |
| Working Capital | $1.04B | $1.84B | $2.72B | $3.49B | $6.26B | $7.42B | $10.49B | $10.60B | $6.03B | $7.34B |
Financial Health
| Debt / Equity | 0.21 |
| Current Ratio | 2.90 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 11.43 |
Profitability
| Return on Equity | 21.18% |
| Return on Invested Capital | 18.12% |
| Return on Assets | 15.12% |
| Gross Margin | 85.03% |
| Operating Margin | 39.43% |
| Net Margin | 32.74% |
Related companies: ARGX · BMY · CVS · GSK · HCA · MCK · MDT
Explore sector: Healthcare · Biotechnology
More sections of VRTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks